For example, in the Swedish National Guidelines for Management of Musculoskeletal Diseases issued by the National Board of Health in 2012 (110), testing for anti-CCP2 antibodies was recommended in all patients with undifferentiated arthritis (i.e. patients with clinical arthritis but not sufficient findings to make a diagnosis of RA or any other established rheumatic disorder). Here, AGBL2 is linked to rheumatoid arthritis.